Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

LALindsay AtonLMLisa Morere

Discussion

Loading...

Member takes

Overview

Retrospective cohort analysis shows demographic differences in venetoclax use for CLL, indicating extended therapy duration beyond guidelines.

Key Points

  • This research evaluates real-world treatment patterns and characteristics of patients receiving venetoclax for chronic lymphocytic leukemia.
  • Utilized the IntegraConnect PrecisionQ Database of 3 million deidentified community oncology patients in the US.
  • Created a retrospective cohort of patients who initiated venetoclax, stratified by first-line and second-line treatments.
  • Conducted descriptive analyses to identify treatment patterns and baseline characteristics.
  • Identified 1590 patients in first-line and 1456 patients in second-line treatments for CLL.
  • Median treatment duration was longer than recommended, with 70.6% on 1L venetoclax for over 12 months.
  • Notable differences in demographics and comorbidities were observed between treatment lines.

Cite This Study

Aton et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d568https://doi.org/10.1182/blood-2025-6317
View Full Paper
Ask AI
Bookmark
Share